It goes without saying that decisions made by NICE apply only to the NHS. Its the message that approval by NICE will send out to other jurisdictions that is probably more important - DCVax-L works and is cost-effective. This will strengthen Northwest Bio's case for licencing by other jurisdictions and make it more difficult for refusal to go unchallenged.
Market Data 
Markets 
AI
